Chinese Academy of Sciences

China's Sinopharm approved clinical trials for a domestically developed mpox vaccine, jointly created by the Beijing Institute of Biological Products and the National Institute for Viral Disease Control and Prevention. The vaccine has shown safety and efficacy in preclinical research, with complete proprietary intellectual property rights. Another Sinopharm subsidiary, the Shanghai Institute of Biological Products, also received approval for clinical trials in September. The Institute of Microbiology under the Chinese Academy of Sciences is researching an mRNA-based mpox vaccine with positive results in mice studies.

China's tech ecosystem excels in diffusion of General Purpose Technologies (GPTs) across sectors, driven by strategic initiatives like Made in China 2025 and Military-Civil Fusion (MCF). This centralized, goal-oriented approach, supported by significant R&D investment and a vast STEM talent pipeline, enhances economic productivity and military prowess. India, by contrast, faces challenges in achieving comparable speed and coherence in its S&T ecosystem, requiring a more unified flow of innovation and stronger private sector participation in R&D.

China's top drug regulator approved clinical trials of a Sinopharm-developed mpox vaccine, which has shown safety and effectiveness in preclinical research. Another Sinopharm subsidiary and the Institute of Microbiology are also researching mpox vaccines. The WHO declared mpox a global health emergency in August, with China reporting 46 infections in September and 38 in October.

The China-Italy Joint Laboratory of Pharmaceutical Biotechnology and Immunosafety launched in Shenzhen aims to promote biopharmaceutical sci-tech achievements. Jointly established by Chinese and Italian institutes, it focuses on immunotoxicity evaluation and immunomodulatory drug development.

China's Tianzhou-8 cargo spacecraft docked with Tiangong space station, delivering 6 tonnes of supplies, including scientific research materials for 36 experiments in space life sciences, biotechnology, and materials science. The studies aim to understand microgravity's effects on life processes and advance human health and space survival technologies.

Shenzhou-19 crew received supplies from Tianzhou-8, carrying 6 tonnes of materials for in-orbit residency, propellants, experiment equipment, and scientific research. Experiments include studying microgravity effects on fruit flies, human stem cells, and mammalian embryos, aiming to advance human health and space survival. Additional studies focus on space materials and new technologies for space applications.

Tsinghua University announced initiatives to advance high-quality medicine development, launching new specialized schools and signing a strategic cooperation agreement with Beijing's Haidian district for a new medical campus. The forum emphasized innovation, interdisciplinary integration, and international collaboration in medical education and research.

Shenzhou-19 crew received supplies from Tianzhou-8, carrying 6 tonnes of materials for in-orbit residency, propellants, experiment equipment, and scientific research. Experiments include studying microgravity effects on life processes and developing advanced spacecraft components.

China's Shenzhou XIX crew received supplies from Tianzhou 8, carrying 6 tonnes of materials including consumables, propellants, and scientific research supplies for 36 experiments in space life sciences, biotechnology, materials science, and more, aiming to advance understanding of microgravity's effects on life processes and support future space missions.